These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1262 related items for PubMed ID: 16048915

  • 1. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [Abstract] [Full Text] [Related]

  • 2. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, Martín-Dávila P, Moreno S.
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [Abstract] [Full Text] [Related]

  • 3. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J, Tang YQ, Sun JY.
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [Abstract] [Full Text] [Related]

  • 4. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
    Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A.
    Int J Antimicrob Agents; 2010 Feb; 35(2):194-9. PubMed ID: 20006471
    [Abstract] [Full Text] [Related]

  • 5. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME.
    Crit Care; 2005 Feb; 9(1):R53-9. PubMed ID: 15693967
    [Abstract] [Full Text] [Related]

  • 6. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
    Zhang JP, Yang XS, Chen J, Peng YZ, Huang YS.
    Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
    [Abstract] [Full Text] [Related]

  • 7. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
    Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA.
    Pediatr Infect Dis J; 2009 Feb; 28(2):123-7. PubMed ID: 19116601
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST, Al Omran S, Al Aithan AS, Al Sultan M.
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [Abstract] [Full Text] [Related]

  • 9. Toxicity after prolonged (more than four weeks) administration of intravenous colistin.
    Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A.
    BMC Infect Dis; 2005 Jan 10; 5():1. PubMed ID: 15642116
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC.
    Int J Antimicrob Agents; 2010 Mar 10; 35(3):297-300. PubMed ID: 20045293
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS, Karatza DC.
    Expert Rev Anti Infect Ther; 2010 Sep 10; 8(9):1009-17. PubMed ID: 20818945
    [Abstract] [Full Text] [Related]

  • 15. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
    Li KL, Abad CLR.
    Int J Infect Dis; 2020 Apr 10; 93():9-14. PubMed ID: 31978579
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.
    Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G.
    Eur J Clin Microbiol Infect Dis; 2006 Sep 10; 25(9):596-9. PubMed ID: 16955249
    [Abstract] [Full Text] [Related]

  • 17. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
    Ozsurekci Y, Aykac K, Cengiz AB, Bayhan C, Sancak B, Karadag Oncel E, Kara A, Ceyhan M.
    Diagn Microbiol Infect Dis; 2016 Jun 10; 85(2):233-8. PubMed ID: 27041107
    [Abstract] [Full Text] [Related]

  • 18. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME, Kasiakou SK.
    Clin Infect Dis; 2005 May 01; 40(9):1333-41. PubMed ID: 15825037
    [Abstract] [Full Text] [Related]

  • 19. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study.
    Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G.
    Clin Infect Dis; 2010 Dec 01; 51(11):1238-44. PubMed ID: 20973727
    [Abstract] [Full Text] [Related]

  • 20. A retrospective study on the effects of colistin therapy in children with multidrug-resistant Gram-negative bacterial pathogens: impact of HIV status on outcome.
    Dimitriades K, Morrow BM, Jeena P.
    Arch Dis Child; 2014 Mar 01; 99(3):262-6. PubMed ID: 24170687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.